OVARIAN CANCER and US: solid tumors

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Showing posts with label solid tumors. Show all posts
Showing posts with label solid tumors. Show all posts

Sunday, May 29, 2011

Expert Opinion on Investigational Drugs -Investigational antibody drug conjugates for solid tumors Summary (Pfizer)



Note: access to the full article is payer-per-view ($$$)

"Despite the progress made in the past 20 years in understanding the molecular events leading to the formation of cancer, the success of targeted antitumor agents in solid tumors has lagged behind the scientific discoveries. The most difficult to treat patient segments are those with refractory solid tumors, resistant to standard chemotherapy, and novel therapeutic compounds with improved therapeutic indexes are needed. Antibody drug conjugates (ADCs) are poised to become an important class of cancer therapeutics, as evidenced by the promising objective response rates when administered as single agents to chemorefractory cancer patients..........Herein, we review ADCs (Antibody drug conjugates) targeting solid tumors, with the focus on 11 programs currently undergoing clinical development....)

Wednesday, March 30, 2011

EvidenceUpdates - Interventions for preventing neuropathy caused by cisplatin and related compounds



BACKGROUND:
Cisplatin and several related antineoplastic agents used to treat many types of solid tumors are neurotoxic, and most patients completing a full course of cisplatin chemotherapy develop a clinically detectable sensory neuropathy. Effective neuroprotective therapies have been sought.


AUTHORS' CONCLUSIONS:
At present, the data are insufficient to conclude that any of the purported chemoprotective agents (acetylcysteine, amifostine, calcium and magnesium, diethyldithiocarbamate, glutathione, Org 2766, oxycarbazepine, or Vitamin E) prevent or limit the neurotoxicity of platin drugs among human patients.

Thursday, January 27, 2011

CCR Clinical Trials at NIH: Clinical Research: results - 22 solid tumor (adult)



Search for Clinical Trials at NIH
The NCI Center for Cancer Research (CCR) conducts more than 150 cancer clinical trials at theNational Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. Cancer clinical trialsthat take place at the NIH Clinical Center are open to patients with cancer, regardless of where they live in the United States.

There are 22 clinical trials at NIH that match your search criteria
*Cancer by type/disease: Solid Tumor (Adult)

Saturday, August 21, 2010

Molecular Markers in Solid Tumors: What Clinicians Need to Know: Introduction - solid tumors



For ovarian cancer, in vitro chemotherapy sensitivity and resistance assays are cited as Category 3 recommendations (reflecting major disagreement among NCCN panel members) for the selection of chemotherapy when multiple appropriate chemotherapy choices exist. Such assays are used in a few NCCN Member Institutions but should not supplant standard of care chemotherapy choice due to the lack of evidence for clinical benefit.[100,101] The NCCN Guidelines™ also recommend that patients with ovarian cancer undergo measurement of serum carbohydrate antigen (CA)-125 levels and "other tumor markers as clinically indicated" at diagnosis, during treatment as markers of response, and as surveillance for disease recurrence.[102,103] Of note, the European Organization for Research and Treatment of Cancer (EORTC) 55955 trial showed no survival benefit when an elevation in CA-125 levels alone was used to prompt initiation of second-line treatment in 1442 patients with ovarian cancer in remission after first-line platinum-based chemotherapy, suggesting against a role for this marker in surveillance for recurrence.[104] Other serum markers may include inhibin for sex cord-stromal tumors and HCG, AFP, and LDH for germ cell tumors of the ovary.[103,105]

Friday, August 13, 2010

Future Medicine - Full Text Cancer pharmacogenomics: do cancer cell lines have the right stuff?



Note: cell 'lines' (test tube) vs  patient tumors

"....But with all the effort and money being put into pharmacogenomics research using cancer cell lines, it is appropriate to ask: how faithfully do cancer cell lines represent the tumors that they are being used to model?"

"Next, do cancer cell lines behave similarly to the tumors they are intended to model to be useful for pharmacogenomics research? First, cancer cell lines are more appropriate for assessing the response to cytotoxic anticancer drugs, rather than the response to newer biologic agents which exert their anti-tumor effects via mechanisms other than eliciting cell death. Second, an important consideration to keep in mind when using cancer cell lines for pharmacogenomics research is that cell lines are generally more sensitive to cytotoxic agents than solid tumors.

"Another important question is: how well does testing in cancer cell lines predict responses in clinical trials with real world patients? When assessing whether there is a correlation between drug activity in Phase II clinical trials and preclinical activity in cancer cell line models, one study found that preclinical activity did not correlate with Phase II response, with the exception of non-small-cell lung cancer [5].

However, ..........It is becoming more and more apparent that the process of culturing cells in vitro alters the genetic make-up of the cancer cell lines."

Wednesday, February 24, 2010

Editorial: Whither HER2-Related Therapeutics? (breast cancer) -- Journal of Clinical Oncology



Note: references to solid tumours

"Evidence suggests that most solid tumors, regardless of their type, cannot grow beyond approximately 1 mm3 until they establish a blood supply by inducing new blood vessels from existing host capillaries, called tumor-induced angiogenesis......It follows then that tumor cells with low HER3 mRNA are more likely to respond to pertuzumab, given that these are the cells where the pathway is activated. We would conjecture that this signature does not apply exclusively in ovarian cancer, but may also be found in other solid tumors, such as non–HER2-positive breast, colorectal, and so on."

Monday, January 25, 2010

A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors - Full Text View - ClinicalTrials.gov



A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors - Full Text View - ClinicalTrials.gov:
"This study has been completed.
First Received: April 23, 2007 Last Updated: September 23, 2009
Sponsor: Poniard Pharmaceuticals
Information provided by: Poniard Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00465725"